article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – May

SQA

The review has two purposes: To ensure devices included in the ARTG continue to meet the essential principles set out in the Therapeutic Goods (Medical Devices) Regulations 2002. World Health Organization (WHO). These features can be restored with a SmartSync programmer session with your cardiologist.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

This proposal builds upon the existing legal framework, which came into force in 2002 for blood and 2004 for tissues and cells. It also fosters innovation in this crucial biotech sector. The framework contains parallel provisions for donor selection, quality and safety management and oversight.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

These are requirements of the Therapeutic Goods (Medical Devices) Regulations 2002. World Health Organization (WHO) Medical Product Alert N°7/2023: Falsified DEFITELIO (defibrotide), 04 September 2023 This WHO Medical Product Alert refers to one falsified batch of DEFITELIO (defibrotide sodium).

FDA 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

Sponsors need to have systems in place to monitor the performance of the devices they supply, receive, update, and maintain information about their devices and report details of adverse events and performance issues to us.These are requirements of the Therapeutic Goods (Medical Devices) Regulations 2002.

FDA 40